Quince Therapeutics, Inc. 近日宣布，其针对肺动脉高压（PAH）及肺动脉高压相关性间质性肺病（PH-ILD）的二期临床研究取得了积极成果。数据显示，在功能评估、血流动力学参数以及关键生物标志物等多个核心测量指标上，均观察到了具有临床意义的显著改善。这一进展为后续的临床开发奠定了重要基础。
Quince Therapeutics, Inc. 近日宣布，其针对肺动脉高压（PAH）及肺动脉高压相关性间质性肺病（PH-ILD）的二期临床研究取得了积极成果。数据显示，在功能评估、血流动力学参数以及关键生物标志物等多个核心测量指标上，均观察到了具有临床意义的显著改善。这一进展为后续的临床开发奠定了重要基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.